For years, the cannabis industry has treated federal rescheduling like a finish line. It isn’t.
Cannabis’s reclassification to Schedule III, will provide some tax benefits and open a new market pathway, but the result won’t be a unified, legitimate industry—it’ll be a split one: two systems, two rulebooks and no clear bridge between them. Once cannabis leaves Schedule I, many believe the regulatory fog will lift and the industry will operate like any other legitimate sector. But in reality, the outcome will be less dramatic—and more complicated.
First, it’s worth invoking a common industry argument: that fog isn’t going to lift until cannabis is descheduled, not rescheduled. Until it’s removed entirely from the Controlled Substances Act, it’s not going to resemble the more straightforward regulation in familiar industries like alcohol and tobacco. And for that to happen, it would require a politically intensive act of Congress that’s just not on the horizon today. For now, the path forward runs through rescheduling.
And that might actually mean the fog just gets foggier for a while. Schedule III designation won’t unify the cannabis industry. Instead, it’ll formalize a divide between operators seeking to become Schedule III-compliant and those that continue functioning under state regulatory systems. These are fundamentally different models, with different standards, distribution and market structures. There’s no practical way to operate in both at once.
And without new federal legislation—not merely reclassification—that policy gap’s unlikely to be resolved soon.
If cannabis moves to Schedule III without new legislation or meaningful federal rulemaking, state markets will largely continue as they do today. Regulators—particularly the DEA—historically avoid sweeping changes that expand or legitimize emerging industries. In practical terms, the supply chain remains intact: Cultivators grow under state licenses, manufacturers produce branded products and dispensaries continue selling through state-regulated systems.
The only real shift is federal classification. The underlying tension doesn’t go anywhere.
Where Schedule III actually makes a difference is through a second, totally new, pathway that emerges for companies operating fully within the federal system: pharmaceuticals.
Schedule III substances are governed by the Controlled Substances Act and move through tightly regulated pharmaceutical supply chains—very different from the state cannabis model. Production requires DEA compliance, security and quotas; distribution runs through licensed channels, with physicians and pharmacists controlling access.
Dispensaries don’t fit into that framework. They never have.
Instead, federally compliant cannabinoid products would likely flow through traditional healthcare channels, including pharmacies and, potentially, compounding pharmacies (specialized pharmacies that prepare customized medications by mixing ingredients in the exact strength, dosage and form prescribed by a doctor). Controlled substances in the US are typically prescribed and dispensed, not sold in retail storefronts. Think prescriptions, not budtenders.
So, the real question for Schedule III cannabis is: Does the plant move into a prescription model tailored to each patient—or stay a dispensary product? It would likely follow a physician–pharmacy model, but without the mass prescription dynamics of the pill mill era, leaning instead toward individualized treatment.
With limited federal guidance and low physician familiarity, pharmaceutical compounding may become the bridge—patient-specific cannabinoid formulations prepared by pharmacies using regulated inputs.
Schedule III substances can be both approved drugs and pharmacy-prepared formulations. In many international markets, physicians prescribe patient-specific cannabinoid therapies that pharmacies prepare using regulated inputs. These magistral preparations—common across Europe, including in Germany and Netherlands—operate within pharmaceutical systems, not retail dispensaries.
A similar pathway could emerge in the US, where physicians prescribe, compounding pharmacies prepare and federally compliant producers supply inputs. That model would look far more like international medical frameworks than the American dispensary system—creating a parallel pharmaceutical cannabis market alongside existing state retail channels, with open questions about overlap and participation.
US operators shouldn’t overlook the international dimension. Many cannabis companies abroad already function within regulatory systems resembling a federally controlled Schedule III framework—particularly across Europe and Latin America, where medical regimes require pharmaceutical-grade standards, controlled substance tracking and government-authorized export structures.
In effect, these operators are accustomed to FDA- and DEA-like oversight. That experience could give them an edge if a federally compliant cannabinoid supply chain emerges in the US.
That advantage, however, has limits. Familiarity with regulated medical markets does not translate to access in the US, where state systems are siloed, tightly licensed and largely closed. While international operators may find opportunity in a federal channel, state markets will remain mostly off-limits without significant federal or state restructuring.
The most immediate consequence of rescheduling, for both state and federally compliant businesses, isn’t structural—it’s financial. Tax Section 280E would no longer apply, allowing cannabis businesses to deduct ordinary expenses for the first time in decades. That alone could improve margins, reshape valuations and align financial practices more closely with traditional industries.
But the impact isn’t uniform.
Some large operators have deferred or disputed substantial 280E liabilities, treating them as future obligations rather than current payments. Others—especially smaller businesses—have absorbed those costs annually. For them, relief could materially improve cash flow and stability.
There are also emerging legal theories challenging 280E’s current application, though these remain complex and fact-specific. The broader point is simple: The industry’s tax burden has never been consistent—and reform won’t change that overnight.
So what does this all lead to? State cannabis businesses will largely continue operating as they do today, serving consumers through dispensaries and mostly vertically integrated supply chains. Meanwhile, federally compliant Schedule III cannabinoid medicines may emerge through controlled pharmaceutical channels—manufacturers, physicians and pharmacies.
Two regulatory logics.
Two supply chains.
Two markets.
Schedule III may not be the destination many imagined, but it’ll set the industry in motion toward a very different future. We can add cannabis to that category of great unknowns.
This story was originally published in the print edition of Cannabis Now Magazine (Issue 53) on April 20, 2026 (just a few days ahead of the rescheduling on April 23).
